An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies

The agonistic potentials of therapeutic anti-CD40 antibodies have been profiled in relation to antibody isotype and epitope specificity. Still, clinical impact relies on a well-balanced efficacy versus target-mediated toxicity. As CD40-mediated immune activation must rely combination stimulation antigen-presenting cells (APCs) alongside antigen presentation, for efficient T cell priming, alternative approaches improve the outcome CD40-targeting strategies should focus providing optimal presentation together with CD40 stimulation. Herein, bispecific targeting as means deliver cargo (i.e., synthetic peptides) into APCs through non-covalent, high-affinity interaction between peptide, further referred Adaptable Drug Affinity Conjugate (ADAC) technology, has developed. ADAC platform demonstrated target-specific improved CD4+ CD8+ expansion vitro significantly peptide-specific proliferation vivo. In addition, strategy dramatically vivo half-life peptides. Future applications involve pandemic preparedness viral genetic drift well neoepitope vaccination where is an off-the-shelf product, peptide synthesized based next-generation sequencing data mining. This article protected by copyright. All rights reserved